Skip to content

Medical emergency? What to do

HPV Vaccine Gets High Marks in Trial

3-RXPublished October 7, 20054 min read

Key points

  • An investigational vaccine aimed at cervical cancer has proved 100% effective against cervical pre-malignant lesions associated with the most prevalent strains of the human papilloma virus (HPV), according to researchers here.
  • In the FUTURE II trial, an international multicenter study, the vaccine protected all 5,301 women who had no study protocol violations for receiving the shots and who were followed for an average of 17 months.
  • The difference in protection was statistically significant at the p<.001 level, said Laura Koutsky, Ph.D., the study's principal investigator, a professor of epidemiology at the University of Washington in Seattle.
  • Merck is expected to file for FDA approval of the vaccine in December.

An investigational vaccine aimed at cervical cancer has proved 100% effective against cervical pre-malignant lesions associated with the most prevalent strains of the human papilloma virus (HPV), according to researchers here.

Results of the Phase III study of Merck's quadrivalent recombinant vaccine, known as Gardisil, are to be presented Friday at the Infectious Diseases Society of America meeting here.

In the FUTURE II trial, an international multicenter study, the vaccine protected all 5,301 women who had no study protocol violations for receiving the shots and who were followed for an average of 17 months.

By comparison, 21 cases of pre-cancerous lesions were detected in 5,258 women given a placebo vaccine. The vaccine, which protected against HPV strains 16 and 18, is given three times: day one, month two, and month six.

The difference in protection was statistically significant at the p<.001 level, said Laura Koutsky, Ph.D., the study's principal investigator, a professor of epidemiology at the University of Washington in Seattle.

“These are the first pivotal data to show that vaccination with Gardasil reduced HPV-16 and 18-related cervical pre-cancer and non-invasive cervical cancer,” she said.

Merck is expected to file for FDA approval of the vaccine in December.

In addition, the researchers followed women who might have missed some of the vaccinations. The results showed that of 5,736 women who received at least some of the inoculations, there was only one case of high-grade pre-malignancy or non-invasive cancer, a 97% reduction. This contrasted with 36 such cases among women in the placebo arm of the trial.

No one dropped out because of serious vaccine-related adverse events. Adverse events were higher among those who received Gardasil compared with placebo recipients, the most common being injection site reactions, Dr. Koutsky said.

Approximately 20 million American men and women are infected with HPV, and HPV types 16 and 18 are responsible for about 70% of all cervical cancer cases. HPV types 6 and 11, also included in the quadrivalent vaccine, are responsible for 90% of cases of genital warts.

Overall, the FUTURE II trial enrolled more than 12,000 women in 13 countries. Participants were 16 to 26 years of age. The study evaluated the prevalence of cervical intraepithelial neoplasia (CIN) Grade 2/3. Grade 2 is a moderate-grade lesion; Grade 3 includes high-grade lesions and carcinoma in situ. It also evaluated the rate of adenocarcinoma in situ. CIN 3 and AIS are both defined as stage 0 cancer by the International Federation of Gynecology and Obstetrics.

"This is the real deal," said Richard Whitley, MD, professor of pediatrics, microbiology, medicine and neurosurgery at the University of Alabama at Birmingham. "The data presented by Merck is the most remarkable vaccine study I have ever seen in my life. This is a significant breakthrough."

Dr. Whitley said he reviewed the data and is convinced that the scientific performance of the study is accurate and that the finding of 100% protection is accurate.

"However," he said, "this is not a real world setting. These women were carefully screened and followed in this study. We don't know what the results will be when we start inoculating larger numbers of women and follow them for longer periods of time."

The women in the study were all free of HPV infection when the trial began. Dr. Whitley said further studies will have to determine whether the vaccine is therapeutic -- that is will it protect women who are already infected from undergoing transformation that results in cancer.

He also said the data do not deal with older women in their 30s and 40s or younger girls. "We also don't know whether there will be booster shots required to maintain protection," he said.

Dr. Whitley said that he expects the FDA will require extensive Phase IV postmarketing studies that may answer a number of those questions.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.